Skip to main content
v2026.1714 entries · CC-BY 4.0
CASRAI
Research Ethics & IRB Guidelines

Ethics & Informed Consent: Randomised Controlled Trial (RCT) (Italy)

A detailed academic review of the ethical submission protocol, informed consent prerequisites, and reporting standards for conducting a Randomised Controlled Trial (RCT) within the regulatory framework of Italy.

Regionally Linked Publications3,277,690
Aggregated Scholarly Citations228,347,887
Tracked Infrastructure Nodes (ROR)15

1. Ethical Principles & Legislative Framework

In research involving human participants, securing ethical clearance is a critical first step. For a Randomised Controlled Trial (RCT) being conducted in Italy, study designs must align with the primary regulatory legislation: Legislative Decree 52/2019 & AIFA Clinical Trial Guidelines. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.

National Ethics Board Clearance Pathway

In Italy, ethics reviews are centralized under designated Comitati Etici Territoriali. The Italian Medicines Agency (AIFA) must be notified for clinical drug/device studies.

Administrative review and formal approval are managed by a local or regional Comitato Etico Territorialmente Competente (Territorial Ethics Committee). Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.

2. Study Design Elements & Reporting Integrity

For a Randomised Controlled Trial (RCT), the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.

Study Classification: High Risk (Interventional)

This interventional trial requires strict protocol adherence, allocation concealment, robust adverse event monitoring, and emergency unblinding guidelines.

To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: CONSORT statement.

Special Directive: Interventional Study Protocols

Because this study design is classified as interventional, the Comitato Etico Territorialmente Competente (Territorial Ethics Committee) requires pre-registration of the trial on a public clinical registry (e.g. ClinicalTrials.gov or a regional WHO-compliant database) before patient enrolment begins. A detailed adverse event reporting protocol must also be submitted.

3. Informed Consent & Information Sheet Guidelines

A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:

Design-Specific Consent Focus Areas

Disclosure of placebo controls, monitoring of adverse events, side effect profiles, and random assignment protocols.

  • Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
  • Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
  • Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under EU GDPR & Italian Privacy Code (Decree 101/2018).
  • Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
  • Ethics Board Contact Information: Provide the contact details of the reviewing Comitato Etico Territorialmente Competente (Territorial Ethics Committee) so participants can reach out if they have questions or concerns.

Research Ethics, Clinical Trials & Institutional Governance

Protecting trial subjects during this Randomised Controlled Trial (RCT) in Italy is rooted in the Belmont Report principles that guide modern medicine. Under active regulations, investigators must explicitly justify if any temporary deception in psychological research is planned for patients. Drafting an exhaustive research study consent form ensures compliance with the informed consent Belmont Report guidelines. Pre-requisites for starting the trial include a formal clinical trial registration and a signed clinical trial agreement contract. If animal models are used, investigators must detail compliance with the 3rs replacement reduction refinement of laboratory models. All records and signed consent sheets must reside on secure local servers in Italy to protect patient privacy and comply with national guidelines.

4. Regulatory Checklist Table

To streamline your ethical review submission, use the structured alignment checklist below:

RequirementComitato Etico Territorialmente Competente (Territorial Ethics Committee) StandardCONSORT statement Standard
Consent FormSigned and dated prior to study activity. Focus: Disclosure of placebo controls.Fully documented recruitment and consent paths.
Risk ManagementComprehensive risk mitigation plan. Mandates establishing an independent Data Safety Monitoring Board (DSMB) and registering the trial on a public registry (e.g., ClinicalTrials.gov).Adverse events reporting strategy.
Data RetentionCompliance with local data protection rules (EU GDPR & Italian Privacy Code (Decree 101/2018)).Provision of open-data options where possible.

5. Academic & Research Infrastructure Matrix (Italy)

The following authenticated registry lists top scientific organizations, clinical laboratories, and research hospitals in Italy mapped via the Research Organization Registry (ROR) standards-compliance framework.

Organization NameSector TypeRegistry Identification
Uriach Italy S.r.l.companyROR ID
Eurosets (Italy)companyROR ID
Baxter (Italy)companyROR IDWikidata/Wiki
Mastelli (Italy)companyROR ID
Konpharma (Italy)companyROR ID
Panin (Italy)companyROR ID
Phoenix (Italy)companyROR ID
Guna (Italy)companyROR ID
Redax (Italy)companyROR ID
Lofarma (Italy)companyROR ID
Lundbeck (Italy)companyROR ID
Lusofarmaco (Italy)companyROR ID
Bayer (Italy)companyROR IDWikidata/Wiki
Takeda (Italy)companyROR IDWikidata/Wiki
Mipharm (Italy)companyROR ID

6. Frequently Asked Questions

How long does the review process normally take?

Review timelines depend on the volume of applications and whether your proposal qualifies for expedited review. On average, a standard review by an ethics board in Italy takes between 4 to 8 weeks.

Can we use digital signatures for informed consent?

Yes, digital consent forms are increasingly accepted, provided the platform used is secure, authenticates the identity of the signer, and complies with local regulations such as the eIDAS or ESIGN Act, depending on country-specific rules.

Regulatory Context

CountryItaly (IT)
Ethics BoardComitato Etico Territorialmente Competente (Territorial Ethics Committee)
Primary LegislationLegislative Decree 52/2019 & AIFA Clinical Trial Guidelines
Privacy RegulationEU GDPR & Italian Privacy Code (Decree 101/2018)
Study DesignRandomised Controlled Trial (RCT)
Reporting StandardCONSORT statement

Verified Funding Bodies

Funder registries and DOI configurations verified for compliance in Italy via Crossref.

  • Ministero della SaluteID: 501100003196 | Location: Italy
  • Sons of Italy FoundationID: 100002345 | Location: United States
  • British Council ItalyID: 501100014595 | Location: Italy
  • US-Italy Fulbright CommissionID: 100015965 | Location: Italy
  • Fondazione ItaliaID: 100018348 | Location: United States
  • Banca d'ItaliaID: 501100003770 | Location: Italy
  • Mundipharma Pharmaceuticals srlID: 501100013124 | Location: Italy
  • Association for the Study of Modern ItalyID: 100014685 | Location: United Kingdom
  • Consiglio Nazionale delle RicercheID: 501100004462 | Location: Italy
  • Roche ItaliaID: 100014805 | Location: Italy

Pre-Submission Warning

Do not recruit participants or initiate study procedures before receiving official written approval from your reviewing board. Ethical approvals cannot be granted retrospectively under Legislative Decree 52/2019 & AIFA Clinical Trial Guidelines.

Referenced across the research world

University of Cambridge logoColumbia University logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoCrossref logoUniversity of Cambridge logoColumbia University logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoCrossref logo
  • University of Cambridge logo
  • Columbia University logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo
  • Crossref logo

View CASRAI adoption →